Talecris Biotherapeutics, Inc.
|Talecris Biotherapeutics, Inc. Patent applications|
|Patent application number||Title||Published|
|20120009650||COMPOSITIONS, METHODS AND KITS FOR PREPARING PLASMINOGEN AND PLASMIN PREPARED THEREFROM - Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.||01-12-2012|
|20110318770||COMPOSITIONS, KITS AND METHODS FOR DETERMINING PLASMIN ACTIVITY - Compositions, kits, and methods for determining plasmin activity using a fluorogenic peptide substrate are provided.||12-29-2011|
|20110237781||METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR - Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods.||09-29-2011|
|20110213126||TWO-STAGE ULTRAFILTRATION/DIAFILTRATION - The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach.||09-01-2011|
|20110004411||METHOD FOR ADJUSTING RESULTS OF A POLYMERASE CHAIN REACTION (PCR) INSTRUMENT - Methods of managing results of a real-time polymerase chain reaction (PCR) instrument and software associated with such methods are described herein. One disclosed method, among others, comprises calculating, from results of the real-time PCR instrument, a fluorescence signal of a sample during a cycle of a baseline period of the real-time PCR instrument. The method further comprises determining whether or not the fluorescence signal during the baseline period increases by at least a certain percentage compared to cycles outside the baseline period. The sample is flagged as a potentially high-titer sample when the fluorescence signal increases by at least the certain percentage.||01-06-2011|
|20110003332||RECOMBINANTLY MODIFIED PLASMIN - Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.||01-06-2011|
|20100304465||Recombinantly Modified Plasmin - Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.||12-02-2010|
|20100196875||HUMAN ERYTHROVIRUS - Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.||08-05-2010|
|20100104551||METHOD FOR PROLONGING ACTIVITY OF AUTODEGRADABLE ENZYMES AND COMPOSITIONS THEREOF - A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.||04-29-2010|
|20100093982||DEVICE AND METHOD FOR PRECIPITATION OF PEPTIDES - The present invention relates to a method for precipitation of peptide where the mixing step of the peptide with the precipitation aid and the precipitation itself are specially separated.||04-15-2010|
|20090269359||Method of Treatment and Prophylaxis of Diseases Related to Amyloid Deposition Using IGM - The invention relates to a method of treating or preventing disease associated with β-amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations.||10-29-2009|
|20090232798||METHODS AND COMPOSITIONS FOR TREATING HERPES INFECTIONS - A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.||09-17-2009|
Patent applications by Talecris Biotherapeutics, Inc.